Bromantane
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Bromantane is listed as actoprotector / atypical psychostimulant (non-peptide).
- •Fatigue resistance
- •Physical work capacity
- •Asthenia (Russian clinical use)
- •Motivation and drive
- •Heat and exertion tolerance
- •Anxiolytic-stimulant profile
Regulatory status: Approved in Russia as Ladasten for asthenic disorders; not FDA-approved and sold elsewhere as a research chemical. Prohibited in sport by WADA..
Structure & Properties
Compound: Bromantane; also known as Ladasten, ADK-709, N-(4-bromophenyl)-adamantan-2-amine.
Pharmacologic class: Actoprotector / Atypical Psychostimulant (non-peptide).
Known delivery routes: Oral.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Synthetic adamantane derivative — not a peptide. Upregulates tyrosine hydroxylase and aromatic L-amino acid decarboxylase expression, increasing dopamine synthesis rather than forcing release; also raises GABA-A/serotonergic tone, producing a combined stimulant-anxiolytic (actoprotector) effect with low tolerance and no classic crash.
- •Reduced physical and mental fatigue without jitteriness
- •Improved endurance and work capacity under heat or exertion
- •Anxiolytic alongside stimulation — unusual dual profile
- •Low tolerance and minimal withdrawal reported in short courses
Human Research
Evidence grade: Clinical RCT (Limited)
Clinical RCT (Limited). Multi-week Russian RCTs in asthenia and neurasthenia report improved fatigue and anxiety scores; no Western Phase III program exists..
Laboratory Research
Multi-week Russian RCTs in asthenia and neurasthenia report improved fatigue and anxiety scores; no Western Phase III program exists.
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Once daily in the morning, with or shortly after food. Effects build over several days; avoid dosing after early afternoon due to sleep interference.
Potential interactions and combinations to avoid
- •MAO inhibitors and dopaminergic drugs (levodopa, bupropion, stimulants) — additive dopaminergic load
- •Antipsychotics / dopamine antagonists — opposing mechanisms
- •Other stimulants late in the day — insomnia risk
- •Alcohol — unpredictable CNS effects
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Dopaminergic overstimulation, insomnia if dosed late
- •Irritability, headache, dry mouth
- •Long-term dopaminergic safety unstudied outside Russia
- •Research-chemical supply — purity and dose accuracy unverified
- •Doping violation for tested athletes
Contraindications
- •Pregnancy or breastfeeding
- •Psychosis, bipolar disorder, or mania history
- •Uncontrolled hypertension or arrhythmia
- •Concurrent MAO inhibitors or dopaminergic agents
- •Under 18 years of age
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 50–100 mg/day (Russian asthenia trials used 50–100 mg; research use rarely exceeds 150 mg)
Frequency: Once daily in the morning
Cycling: Typical use is 2–4 weeks on followed by an equal break. Continuous dosing beyond 4–6 weeks is not supported by the available trial data.
Oral
Standard route — small lipophilic molecule, not a peptide; no reconstitution required.
Capsule, tablet, or weighed powder (mg scale required — doses are small). Single morning dose with or without food; fat-containing food may improve absorption. Avoid afternoon/evening dosing — stimulating effects can disrupt sleep.
Sold as a research chemical in most markets; purity and label accuracy are unverified.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Semax or Selank — commonly paired for cognition and stress tolerance
- •Sleep, hydration and structured training blocks for fatigue resistance
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Not a peptide — a synthetic adamantane actoprotector. Typical research use is 2–4 weeks on, then a break, to limit tolerance. WADA-prohibited in competition.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Morning — mild stimulant-like effect can disturb sleep if taken late.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
Bromantane has no injection site — see the routes below.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Typical use is 2–4 weeks on followed by an equal break. Continuous dosing beyond 4–6 weeks is not supported by the available trial data.
Timing & Interactions
- ·MAO inhibitors and dopaminergic drugs (levodopa, bupropion, stimulants) — additive dopaminergic load
- ·Antipsychotics / dopamine antagonists — opposing mechanisms
- ·Other stimulants late in the day — insomnia risk
- ·Alcohol — unpredictable CNS effects
- ·Semax or Selank — commonly paired for cognition and stress tolerance
- ·Sleep, hydration and structured training blocks for fatigue resistance
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Bromantane and sync them to Vial Lab.
Benefits
- ·Reduced physical and mental fatigue without jitteriness
- ·Improved endurance and work capacity under heat or exertion
- ·Anxiolytic alongside stimulation — unusual dual profile
- ·Low tolerance and minimal withdrawal reported in short courses
Risks
- ·Dopaminergic overstimulation, insomnia if dosed late
- ·Irritability, headache, dry mouth
- ·Long-term dopaminergic safety unstudied outside Russia
- ·Research-chemical supply — purity and dose accuracy unverified
- ·Doping violation for tested athletes
Contraindications
- ·Pregnancy or breastfeeding
- ·Psychosis, bipolar disorder, or mania history
- ·Uncontrolled hypertension or arrhythmia
- ·Concurrent MAO inhibitors or dopaminergic agents
- ·Under 18 years of age
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Approved in Russia as Ladasten for asthenic disorders; not FDA-approved and sold elsewhere as a research chemical. Prohibited in sport by WADA.
Veterinary Use (Pets)
No established veterinary protocol for Bromantane. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →